IgG4 isotopen er Unibody og ikke Ultimab (IgG1)

Unibody er altså en aktiv platform for Genmab med en aftale med Lundbeck og der arbejdes på flere targets bl.a. med anti-cd89 (astma) og C-Met der har følgende beskrivelse af funktionen:

The receptor tyrosine kinase c-Met is prominently expressed on a wide variety of epithelial cells. During embryogenesis, cMet and Hepatocyte Growth factor/Scatter factor (HGF/SF) are involved in tissue-specific differentiation, leading to a proper organization of epithelial cells, muscle endothelium, and the nervous and hematopoietic systems. Abnormal cMet signalling has been implicated in tumorogenesis, particularly in the development of invasive and metastatic tumors. As a consequence of enhanced cMet activity, tumor cells may increase their growth rate and become resistant to apoptosis, resulting in a growth and/or survival advantage. Furthermore, cMet activation may lead to cytoskeletal reorganization and integrin activation, as well as to activation of proteolytic systems involved in extracellular matrix degradation, resulting in an increased invasive and metastatic capacity. Inhibition of HGF/SF-cMet signaling, therefore, represents an important therapeutic avenue for the treatment of malignant tumors.

Afsnittet er i: Example 56 Proof of Concept Study with Hingeless IgG4 cMet (cMet-HG)

Flere biotech arbejder på C-Met target bl.a. ARQL, EXEL og PFE